95 completed, 41 recruiting, 36 terminated, 16 active not recruiting. 154 Phase 2, 62 Phase 1, 17 Phase 3, 10 Not applicable, 4 Early Phase 1.
Follow Total Body Irradiation: new trials by email Literature Review of Total Body Irradiation trials Research Report on Total Body Irradiation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma Allogeneic Hematopoietic Stem Cell Transplantation, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Cyclophosphamide - Multiple Myeloma, Recurrent Multiple Myeloma | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2027-06-01 | 2026-09-11 | |
| Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Biopsy - Acute Myeloid Leukemia | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 244 | 2027-01-15 | 2026-10-20 |
| Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 52 | 2027-01-01 | 2026-09-14 |
| Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma Biospecimen Collection, Computed Tomography, Cyclophosphamide - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Recruiting | Nathan Denlinger | 18 | 2026-12-01 | 2026-10-09 |
| Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers Cyclophosphamide, Busulfan, Fludarabine - Core Binding Factor Alpha Subunits, Hematologic Neoplasms | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 102 | 2026-10-28 | 2026-10-23 |
| Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors Total Body Irradiation, Alemtuzumab, Abatacept - Sickle Cell Disease, Beta-thalassemia | Phase 1 / Phase 2 | Recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 90 | 2026-07-08 | 2026-10-13 |
| Cord Blood Transplantation in Children and Young Adults With Blood Cancer Cord Blood Units, Total Body Irradiation, Cyclophosphamide - Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 71 | 2026-04-28 | 2026-05-14 |
| Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma Bendamustine, Pralatrexate, Bone Marrow Aspiration - Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 50 | 2026-04-27 | 2026-05-11 |
| MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases Treosulfan, Fludarabine, Total Body Irradiation - AML, MDS | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 132 | 2026-04-10 | 2026-04-16 |
| ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis Cyclophosphamide, Fludarabine, Thiotepa - Acute Myelogenous Leukemia, Acute Lymphatic Leukemia | Phase 2 | Suspended | Leland Metheny | 20 | 2026-04-08 | 2026-09-10 |
| Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation mCD19-CAR-CD28-CD3-zeta.(anti-CD19 CAR) retroviral vector-transduced allogeneic peripheral blood lymphocytes (PBL), Fludarabine, Cyclophosphamide - Hematologic Malignancies, Hematologic Neoplasms | Phase 1 | Recruiting | National Cancer Institute (NCI) | 155 | 2025-11-14 | 2026-10-16 |
| Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 20 | 2025-09-26 | 2026-07-20 |
| Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Aplastic Anemia | Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 1 | 2025-09-25 | 2026-05-22 |
| Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Acute Undifferentiated Leukemia | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 36 | 2025-09-23 | 2026-05-15 |
| Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System, Prednisone/Methylprenisolone, Palifermin - Crohn Disease | Phase 1 / Phase 2 | Not yet recruiting | Stanford University | 14 | 2025-07-01 | 2025-05-23 |
| 131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD) 131I-apamistmab, Sirolimus, Campath - Sickling Disorder Due to Hemoglobin S | Phase 1 | Recruiting | Columbia University | 24 | 2025-04-28 | 2026-06-10 |
| Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function Cyclophosphamide, Ciltacabtagene Autoleucel, Total body irradiation - Multiple Myeloma | Phase 1 | Recruiting | Washington University School of Medicine | 16 | 2024-12-04 | 2026-03-11 |
| Allo HSCT for High Risk Hemoglobinopathies Alemtuzumab, Total Body Irradiation, Cell Infusion - Graft Failure, Sickle Cell Disease | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 62 | 2024-11-19 | 2026-06-04 |
| Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant Venetoclax, Decitabine, Fludarabine - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 2 | Withdrawn | Northside Hospital, Inc. | 2024-08-31 | 2024-06-14 | |
| Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases Biospecimen Collection, Bone Marrow Aspirate, Cyclophosphamide - Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 54 | 2024-07-23 | 2026-07-22 |
Showing 20 of 215. Sign in to see all of them.
Leukemia, Myeloid, Acute (68) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (65) · Myelodysplastic Syndromes (64) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (45) · Hodgkin Disease (41) · Multiple Myeloma (41) · Lymphoma, Non-Hodgkin (39) · Leukemia, Lymphocytic, Chronic, B-Cell (38) · Myeloproliferative Disorders (30) · Leukemia (29) · Hematologic Neoplasms (27) · Lymphoma, Mantle-Cell (26) · Leukemia, Myelomonocytic, Chronic (25) · Leukemia, Biphenotypic, Acute (23) · Lymphoma (23)
Fred Hutchinson Cancer Center (56) · Masonic Cancer Center, University of Minnesota (30) · M.D. Anderson Cancer Center (9) · National Cancer Institute (NCI) (9) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (8) · Baylor College of Medicine (6) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (6) · City of Hope Medical Center (5) · Memorial Sloan Kettering Cancer Center (4) · National Institute of Allergy and Infectious Diseases (NIAID) (4) · Asan Medical Center (3) · Columbia University (3) · Massachusetts General Hospital (3) · Medical College of Wisconsin (3) · Northside Hospital, Inc. (3)
United States (198) · Germany (8) · Canada (6) · Italy (6) · Denmark (5) · France (4) · South Korea (4) · Australia (3) · China (3) · Austria (2) · Poland (2) · United Kingdom (2) · Brazil (1) · Czechia (1) · Israel (1)
Brenda Sandmaier (11) · Filippo Milano (4) · Marie Bleakley (4) · Phuong Vo (4) · Rachel B. Salit (4) · Claudio G. Brunstein, MD, PhD (3) · Elizabeth M Kang, M.D. (3) · Usama Gergis, MD (3) · Alexandra Gomez Arteaga, MD (2) · Amy E DeZern, MD (2) · Christopher G Kanakry, M.D. (2) · Claudio Brunstein, MD (2) · Claudio Brunstein, MD, PhD (2) · Damiano Rondelli, MD (2) · David Maloney (2)
PMID 32499241, PMID 15812540, PMID 21195303, PMID 21403127, PMID 22430088, PMID 22555974, PMID 25310303, PMID 25753432, PMID 33242441, PMID 35007144, PMID 17038533, PMID 18596741, PMID 18997171, PMID 19151774, PMID 19167681, PMID 19179301, PMID 20032498, PMID 20383216, PMID 20564154, PMID 20952687, PMID 21459795, PMID 21508120, PMID 21552302, PMID 21586746, PMID 21680797, PMID 22055111, PMID 22517900, PMID 22564995, PMID 22796534, PMID 22855604, PMID 23432431, PMID 23650429, PMID 24062388, PMID 24319166, PMID 24319167, PMID 24497539, PMID 24687837, PMID 24842530, PMID 25085357, PMID 25354103, PMID 25605857, PMID 25791241, PMID 25797174, PMID 25824692, PMID 25862561, PMID 26022239, PMID 26183076, PMID 26359881, PMID 26869630, PMID 26869631
P30CA015704 (35), P01CA018029 (11), P01CA078902 (7), P01CA044991 (4), P01CA015396 (2), P01HL122173 (2), P30CA016672 (2), R01HL121568 (2), U10CA180888 (2), U24CA076518 (2), 1RC2HL101496 (1), 2009 (1), K12HL087165 (1), K23CA154532 (1), KL2RR025006 (1)